Neonatal diabetes mellitus, defined as insulin-sensitive
hyperglycemia involving the activating mutations in the
KCNJ11 gene encoding Kir 6.2, is diagnosed within the
first six months of life presenting with glucosuria,
polyuria, dehydration, failure to thrive, and diabetic
ketoacidosis [1]. Treatment with insulin results in dramatic
catch-up growth; insulin may be discontinued in about half
these patients, as blood glucose is well-controlled on
sulfonylureas (SUs).
We report a case of neonatal diabetes in
a 4-month-old baby girl presenting with diabetic
ketoacidosis due to p.R201H mutation in the KCNJ11
gene, who was successfully changed from subcutaneous insulin
to oral glibenclamide on an outpatient basis.
The patient, who was being treated
elsewhere as Type 1 diabetic, had an HbA1c of 11.6% with low
serum c-peptide levels (<0.3 ng/mL) on referral. Since
autoimmune diabetes is less common before six months of age,
we considered other possible causes of diabetes. While
awaiting results of genetic analysis, she was initiated on
oral glibenclamide (as a powder dissolved in water) in a
dose of 0.3 mg/kg/day, in three divided doses. Strict self
monitoring of blood glucose was done and the insulin was
gradually tapered off over next few days. Within four days
of starting glibenclamide, repeat serum c-peptide levels
done were better (2.25 ng/mL), indicating increased
endogenous production of insulin. Genetic testing of both
parents was negative for the mutations.
Presently, the patient is doing well,
gaining weight, and is continuing on glibenclamide with a
latest HbA1c of 7.6% and serum c-peptide level of 2.38 ng/mL.
We therefore suggest an outpatient protocol for changing
these patients from insulin to Sulfonylureas(SUs) [2].
SUs are introduced gradually over a
period of weeks as an outpatient. Glibenclamide dose
is increased each week by 0.2 mg per kg per day in divided
doses up to a total daily dose of 1.0 mg per kg per day. It
has been found that the pre-breakfast glucose may be very
slow to fall and pre-lunch or pre-evening meal glucose
values fall more rapidly and are generally a better marker
of response to SUs. In some patients there may be initial
diarrhea but this settles on its own. Care must be taken to
recognize and treat hypoglycemia including the use of 0.5-1
mg glucagon injection for emergency use if unable to take
oral carbohydrate. The physician should see the patient
every week, and be accessible by phone during the transfer.
We emphasize the need for medical
practitioners to consider molecular testing for all patients
who present with diabetes below 6 months of age as this will
facilitate accurate diagnosis and appropriate therapy.
1. Flanagan SE, Edghill EL, Gloyn AL,
Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes
Kir6.2, are a common cause of diabetes diagnosed in the
first 6 months of life, with the phenotype determined by
genotype. Diabetologia. 2006;49:1190-7.
2. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S,
Hattersley AT. Effective treatment with oral sulfonylurea in
patients with diabetes due to sulfonylurea receptor 1 (SUR1)
mutations. Diabetes Care. 2008;31:204-9.